Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program ...

Artificial intelligence (AI) and the Internet of Things (IoT) are about to revolutionize the biopharmaceutical industry.

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential ...

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases ...

Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

House Bill 1879 passed unanimously March 4 on a 95-0 vote, according to the chamber's website. State senators will now ...

AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...